itepekimab: Clinical Trials

7 trials of itepekimab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

3 active not recruiting, 3 completed, 1 withdrawn. 7 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	7	Active not recruiting 3, Completed 3, Withdrawn 1

Follow itepekimab: new trials by email Literature Review of itepekimab trials Research Report on itepekimab

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps	Phase 3	Withdrawn	Sanofi		2026-05-08	2026-08-13
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps	Phase 3	Active not recruiting	Sanofi	59	2026-03-12	2026-10-13
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps	Phase 3	Active not recruiting	Sanofi	231	2025-02-12	2026-10-21
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps	Phase 3	Active not recruiting	Sanofi	216	2025-02-06	2026-10-21
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD Itepekimab (SAR440340), Placebo - Chronic Obstructive Pulmonary Disease	Phase 3	Completed	Sanofi	669	2024-01-11	2026-09-18
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Itepekimab SAR440340, Placebo - Chronic Obstructive Pulmonary Disease	Phase 3	Completed	Sanofi	1234	2021-02-12	2026-10-09
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Itepekimab SAR440340, Placebo - Chronic Obstructive Pulmonary Disease	Phase 3	Completed	Sanofi	1127	2020-12-16	2026-10-15

Conditions studied

Sponsors

Countries

NIH funding